Investment in Midatech Pharma PLC

RNS Number : 4860D
Intuitive Investments Group plc
29 June 2021
 

29 June 2021

Intuitive Investments Group plc

Investment in  Midatech Pharma PLC

Intuitive Investments Group plc (AIM: IIG) ("IIG" or the "Company"), a closed-end investment company focussed on the life sciences sector, announces an investment of £99,750 to acquire 350,000 ordinary shares of Midatech Pharma PLC (" Midatech ") at a price of 28.5 pence per share (the "Investment").  The Investment is part of  Midatech 's fundraising as  announced by Midatech on 29 June 2021 (the "Fundraising").

Midatech ( dual listed on LSE AIM: MTPH; and NASDAQ: MTP) is a drug delivery technology company focussed on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients. Midatech reported a net loss from continuing operations for the year ended 31 December 2020 of £22.2 million (which includes non-cash impairment charges of £12.4 million), and, as at 31 December 2020, had net assets of £6.7m. Further information can be found on Midatech on its website www.midatechpharma.com .

As part of the Fundraising, Robert Naylor, IIG's CEO, has personally invested £242,250. David Evans, IIG's Chairman, has a pre-existing interest of 400,000 warrants over Midatech's ordinary shares.  Accordingly, David Evans nor Robert Naylor voted as members of the Investment Team approving the Investment.

For further information, please contact:

Intuitive Investments Group plc

www.iigplc.com

David Evans, Executive Chairman

Robert Naylor, CEO

Via Walbrook PR

 

 

Strand Hanson Limited - Nominated Adviser

+44 (0) 20 7409 3494

James Dance / James Bellman

 

 

 

Turner Pope Investments (TPI) Ltd - Broker

+44 (0) 20 3657 0050

Andrew Thacker / James Pope

 

 

 

Walbrook PR Limited - Media & Investor Relations

+44 (0)20 7933 8780 or intuitive@walbrookpr.com

Sam Allen / Paul McManus

+44 (0)7502 558 258 / +44 (0) 7980 541 893

About Intuitive Investments Group plc

The Company is a recently established investing company, seeking to provide investors with exposure to a portfolio concentrating on fast growing and/or high potential Life Sciences businesses operating predominantly in the UK, continental Europe and the US, utilising the Board's experience and in particular that of the Chairman, David Evans, to seek to generate capital growth over the long term for shareholders. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQSEDSUUEFSEIM
UK 100

Latest directors dealings